Elafibranor 80mg Tablets

Elafibranor 80mg Tablets represent a cutting-edge therapeutic intervention in the field of hepatology, specifically designed to address the complex pathophysiology of chronic cholestatic liver diseases such as Primary Biliary Cholangitis (PBC). As a first-in-class, dual peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist, this medication offers a unique mechanism of action that distinguishes it from traditional therapies.

The pharmacological efficacy of Elafibranor 80mg Tablets stems from the simultaneous activation of PPAR-alpha and PPAR-delta nuclear receptors. PPAR-alpha activation is crucial for lipid metabolism and the regulation of inflammation, while PPAR-delta plays a significant role in glucose homeostasis and the modulation of inflammatory responses. By targeting these two distinct pathways, the drug exerts a comprehensive beneficial effect on the liver environment.

In the context of cholestasis, the active agent works by reducing the synthesis and toxicity of bile acids, decreasing liver inflammation, and mitigating metabolic dysregulation. This multi-targeted approach leads to a significant reduction in biochemical markers of liver injury, such as alkaline phosphatase (ALP) and bilirubin, thereby preserving liver function and potentially slowing the progression of fibrosis. This therapeutic profile makes it a vital option for patients who have not responded adequately to standard first-line treatments.

Indications / Uses of Elafibranor 80mg Tablets

Elafibranor 80mg Tablets are indicated for the treatment of specific liver conditions in adult patients, offering a targeted approach to managing disease progression and symptoms. The primary indications include:

• Primary Biliary Cholangitis (PBC): This medication is indicated for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
• Reduction of Cholestatic Injury: It is prescribed to lower persistently elevated levels of alkaline phosphatase (ALP), a key surrogate marker for disease progression and transplant-free survival in patients with cholestatic liver disease.
• Management of Hepatic Inflammation: By activating PPAR receptors, the drug helps modulate the immune response within the liver, reducing the chronic inflammation that drives tissue damage and scarring.
• Metabolic Liver Support: Due to its mechanism of action involving lipid and glucose metabolism regulation, it supports overall metabolic health in patients who may suffer from concurrent metabolic liver dysfunction.

Key Features

• Dual Agonist Mechanism: Uniquely targets both PPAR-alpha and PPAR-delta receptors, providing a synergistic effect that addresses multiple drivers of liver disease, including inflammation, cholestasis, and fibrosis.
• Once-Daily Oral Dosing: The formulation allows for convenient once-daily oral administration, which significantly enhances patient adherence compared to more complex regimens.
• Significant Biochemical Response: Clinical studies have demonstrated that treatment with Elafibranor 80mg Tablets leads to rapid and sustained improvements in liver biochemistry, particularly reductions in ALP and bilirubin.
• Improved Tolerability Profile: Unlike some other second-line agents that can exacerbate pruritus (itching), this medication generally demonstrates a favorable side effect profile with no significant worsening of itch symptoms.
• Anti-Inflammatory Properties: Beyond metabolic control, the agent actively suppresses pro-inflammatory cytokines, addressing the autoimmune and inflammatory components of PBC.

Storage for Elafibranor 80mg Tablets

To ensure the pharmacological potency and safety of Elafibranor 80mg Tablets, proper storage is essential. The medication should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the tablets in their original container to protect them from moisture and light. Do not store the medication in humid environments like bathrooms or near kitchen sinks. Keep the container tightly closed when not in use and store it in a secure location, well out of the reach and sight of children and pets to prevent accidental ingestion.

Important Note on Elafibranor 80mg Tablets

Treatment with Elafibranor 80mg Tablets requires careful medical supervision and regular monitoring. Before initiating therapy, a comprehensive assessment of liver function and a pregnancy test for women of childbearing potential are recommended. The standard dosage is one 80mg tablet taken orally once daily, and it can be taken with or without food.

While generally well-tolerated, potential side effects may include abdominal pain, diarrhea, nausea, vomiting, and myalgia (muscle pain). Hypersensitivity reactions can occur; if signs such as rash or swelling appear, medical attention should be sought immediately.

A specific consideration for PPAR agonists is the potential for mild increases in serum creatinine, which are generally reversible. Therefore, renal function should be monitored periodically. Furthermore, as this drug may interact with certain drug metabolizing enzymes (like CYP enzymes) and transporters, it is crucial to review all concomitant medications to avoid potential drug-drug interactions.

Women of childbearing potential should use effective contraception during treatment and for a period after the final dose, as data on use in pregnancy is limited. Patients should be advised not to stop taking Elafibranor 80mg Tablets abruptly without consulting their healthcare provider, as this could lead to a rebound in liver enzyme levels. Always report any new or worsening symptoms, such as severe fatigue or jaundice, to a doctor promptly.